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Ponatinib  is  approved  for adults  with  refractory  chronic  myeloid  leukemia  or Philadelphia
chromosome–positive  acute  lymphoblastic  leukemia,  including  those  with  the T315I BCR-ABL1  muta-
tion.  We pooled  data  from  3 clinical  trials  (N = 671)  to determine  the  impact  of  ponatinib  dose intensity
on  the following  adverse  events:  arterial  occlusive  events  (cardiovascular,  cerebrovascular,  and  periph-
eral vascular  events),  venous  thromboembolic  events,  cardiac  failure,  thrombocytopenia,  neutropenia,
hypertension,  pancreatitis,  increased  lipase,  increased  alanine  aminotransferase,  increased  aspartate
aminotransferase,  rash,  arthralgia,  and  hypertriglyceridemia.  Multivariate  analyses  allowed  adjustment
for  covariates  potentially  related  to  changes  in  dosing  or an event.  Logistic  regression  analysis  iden-
tiﬁed  signiﬁcant  associations  between  dose  intensity  and  most  events  after  adjusting  for  covariates.
Pancreatitis,  rash,  and  cardiac  failure  had  the  strongest  associations  with  dose  intensity  (odds  ratios  >2).
Time-to-event  analyses  showed  signiﬁcant  associations  between  dose  intensity  and  risk  of arterial  occlu-yrosine kinase inhibitor sive events  and  each  subcategory.  Further,  these  analyses  suggested  that a lag  exists  between  a  change
in  dose  and  the  resulting  change  in event  risk. No  signiﬁcant  association  between  dose  intensity  and  risk
of  venous  thromboembolic  events  was  evident.  Collectively,  these  ﬁndings  suggest  a potential  causal
relationship  between  ponatinib  dose  and  certain  adverse  events  and  support  prospective  investigations
of  approaches  to  lower  average  ponatinib  dose  intensity.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. IntroductionBCR-ABL1 tyrosine kinase inhibitors (TKIs) are effective for
mproving outcomes in the treatment of chronic myeloid leukemia
CML) and Philadelphia chromosome–positive acute lymphoblastic
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/).leukemia (Ph+ ALL); however, in many cases, resistance devel-
ops through BCR-ABL1 mutations or other mechanisms [1]. The
T315I mutation occurs in 5% to 20% of imatinib-resistant patients
with BCR-ABL1 mutations and confers resistance to imatinib, dasa-
tinib, nilotinib, and bosutinib [2–6]. Other mutations that may
confer resistance to 1 or more of these drugs include Y253F/H,
E255K/V, F359V/I/C, F317L/V/I/C, and V299L [1]. The BCR-ABL1 TKI
ponatinib is unique in its broad-spectrum efﬁcacy against both
unmutated and mutant forms of BCR-ABL1, including the T315I
mutant [7–9]. Data from the single-arm, open-label phase 2 Pona-
tinib Ph+ ALL and CML  Evaluation (PACE) trial (ClinicalTrials.gov
identiﬁer: NCT01207440), which was conducted in patients in
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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hom dasatinib or nilotinib had failed or who had the T315I muta-
ion, demonstrated the efﬁcacy and safety of ponatinib in patients
ith or without T315I [10] and provided the basis for the regula-
ory approval of ponatinib in 2012. Thus, ponatinib represents an
ffective treatment for patients with limited options.
Data obtained in October 2013 from the ongoing PACE trial
howed that after a median of 24 months of follow-up, pona-
inib was associated with an increased frequency of serious arterial
cclusive events, compared with the frequency reported after 11
onths of follow-up. Recommendations for dose reduction were
mplemented in October 2013 to mitigate the risk of additional
erious adverse events.
In previous retrospective analyses of data from the phase 2 PACE
rial, it was suggested that ponatinib dose intensity had a signiﬁ-
ant association with efﬁcacy and adverse events [11], suggesting
 potential causal relationship. Ponatinib has also been studied
n a single-arm, open-label, phase 1 dose-ﬁnding trial of heavily
retreated patients with CML  or other hematologic malignancies
ClinicalTrials.gov identiﬁer: NCT00660920) [12] and in the ran-
omized, open-label phase 3 Evaluation of Ponatinib vs. Imatinib
n CML  (EPIC) trial in patients with newly diagnosed chronic-phase
ML (ClinicalTrials.gov identiﬁer: NCT01650805) [13]. To further
xplore the association of ponatinib dose intensity with arterial
cclusive disease as well as other adverse events, we conducted
 post hoc pooled analysis of the data from these 3 trials, using
n expanded set of safety measures. The objectives of the pooled
nalysis were: 1) to evaluate the impact of the dose intensity of
onatinib on selected adverse events that are frequent or clinically
elevant, 2) to perform multivariate analyses to allow adjustment
or covariates that may  be related to the event or to decisions
egarding dose reductions or interruptions, 3) to provide infor-
ation on covariates that are predictive of the occurrence of each
dverse event, and 4) to evaluate the timing of dose changes relative
o the occurrence of arterial occlusive events.
. Methods
.1. Patients
Data were pooled from patients with CML, Ph+ ALL, or other
ematologic malignancies who received ponatinib in the phase 1
rial (n = 81), the phase 2 PACE trial (n = 449), or the phase 3 EPIC
rial (n = 153); starting doses of ponatinib were 2–60 mg  once daily,
5 mg  once daily, and 45 mg  once daily, respectively. Each of these
 trials required patients to provide written informed consent, and
ere conducted in accordance with the Declaration of Helsinki, the
nternational Council for Harmonisation, Good Clinical Practice, and
he US Food and Drug Administration regulations for the protec-
ion of the rights and welfare of human patients participating in
iomedical research.
.2. Endpoints
The primary analysis method was logistic regression, with
he outcome deﬁned as the presence or absence of a selected
reatment-emergent adverse event of interest prior to the last
ay of dosing. The primary predictor variable was average dose
ntensity measured up to the day of the event for patients with
n event, and through the date of the last reported dose for
atients without an event. Treatment-emergent adverse events
nalyzed were: arterial occlusive events (including cardiovas-
ular, cerebrovascular, and peripheral vascular events), venous
hromboembolic events, cardiac failure, thrombocytopenia, neu-
ropenia, hypertension, pancreatitis, increased lipase, increased
lanine aminotransferase, increased aspartate aminotransferase,earch 48 (2016) 84–91 85
rash, arthralgia, and hypertriglyceridemia. Cardiovascular, cere-
brovascular, and peripheral vascular events were the subsets of
arterial occlusive events speciﬁcally related to the coronary arter-
ies, the arteries in and around the brain, and the peripheral arterial
system, respectively. Arterial occlusive events and venous throm-
boembolic events were queried through a broad collection of more
than 400 Medical Dictionary for Regulatory Activities preferred
terms related to vascular ischemia or thrombosis. The baseline
covariates that were present in most patients (671 out of 683) in
the pooled analysis and that were potentially related to the events
or to the decision to reduce the dose were: medical history of dia-
betes at study entry (yes/no), medical history of ischemic disease at
study entry (yes/no), age at study entry, log baseline platelet count,
log baseline neutrophil count, number of prior TKIs, and time from
diagnosis to ﬁrst dose.
2.3. Safety
In all 3 trials, investigators were directed to temporarily inter-
rupt and/or reduce the dose of ponatinib to manage adverse events
according to protocol-deﬁned criteria. In addition, in October 2013,
after updated PACE trial data regarding the increased frequency
of serious arterial occlusive events were obtained, the following
prospective dose reductions were implemented across all pona-
tinib clinical trials: 1) for patients with chronic-phase CML  who
achieved major cytogenetic response in the phase 1 and phase 2
trials or who  achieved major molecular response in the phase 3
trial, a dose reduction to 15 mg/d was requested, with an escala-
tion to 30 mg/d allowed upon loss of response; and 2) for all other
patients, a dose reduction to 30 mg/d was  requested. Investigators
were allowed to consider patients’ CML  characteristics, BCR-ABL1
mutation status, and cardiovascular risk in determining whether
other ponatinib doses were justiﬁed. The EPIC trial was  terminated
shortly after these recommendations were implemented [13].
The safety population included all patients who received pona-
tinib. Adverse events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events version
used for each trial (version 3.0 for the phase 1 trial, and version 4.0
for the PACE and EPIC trials).
2.4. Statistical methods
2.4.1. Logistic regression analysis
For each outcome and dose intensity measure, 3 sets of logis-
tic regression analyses were performed: 1) univariate, for dose
intensity and each baseline covariate; 2) full multivariate, which
adjusted simultaneously for dose intensity and all covariates; 3)
reduced multivariate, in which less impactful covariates were
removed from the full model by stepwise regression with backward
selection until all covariates were signiﬁcant at a level of 0.2. Dose
intensity was  calculated as the average daily dose intensity up to the
day of the ﬁrst occurrence of the event of interest in patients expe-
riencing an event, and as the average daily dose intensity through
the last reported dose in patients not experiencing the event of
interest. Dose intensity was not part of the backward selection and
was retained in each model. For each of the 3 logistic regression
models, the results reported included odds ratios for the covariates
and the associated P values for testing the odds ratio = 1.
2.4.2. Time-to-event modeling
To address potential limitations of the logistic regression anal-
yses, time-to-event analyses were performed on arterial occlusive
events (including the subcategories of cardiovascular, cerebrovas-
cular, and peripheral vascular events) and venous thromboembolic
events. These analyses accounted for the timing of the event and
the different durations of patient follow-up, and adjusted for the
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Fig. 1. Examples of lag (time between dosing and event onset) and window (number of dosing days used when averaging the dose intensity). Lags from 0 to 270 days and
windows from 1 to 180 days were used in the models.
Table 1
Ponatinib exposure at different dose levels.
Dose level (mg/d) Any 0 15 30 45
Exposure (patient-years) 931.9 105.2 154.7 209.1 462.9
Exposure (% of total patient-years) 100% 11% 17% 22% 50%
Dose levels shown in table: 0 mg/d indicates dose interruption; 15 mg/d indicates >0 and ≤15 mg/d; 30 mg/d indicates >15 and <45 mg/d; 45 mg/d indicates ≥45 mg/d
(including 60 mg/d).
Table 2
Distribution of prognostic factors by dose intensity quartile (N = 671).
Covariate Lowest quartile:
<25.6 mg/d
Second quartile:
25.6–37.9 mg/d
Third quartile:
>37.9–44.5 mg/d
Highest quartile:
>44.5 mg/d
History of diabetes, % 20.8 14.4 9.5 13.7
History of ischemic disease, % 22.6 22.2 14.9 11.9
Age  at study entry, mean, years 60.9 57.1 50.3 51.8
Baseline platelet count, geometric mean, × 109/L 174.3 204.0 195.3 128.4
Baseline neutrophil count, geometric mean, × 109/L 4.7 5.8 5.5 3.5
Number of prior TKIs, mean 2.3 2.0 1.7 2.0
Time  from diagnosis to ﬁrst dose, mean, years 7.7 5.7 4.7 4.6
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ame covariates as the logistic regression model. Analyses used
aily dosing to help identify the timing of dosing most predictive of
rterial occlusive events and venous thromboembolic events. For
ach event type, a series of different models was created using aver-
ge dose as a time-varying covariate for a series of combinations of
ag and window based on the time of the event. Lag was  deﬁned as
he time between dosing and event onset, and window was  deﬁned
s the number of days of dosing to use when averaging the dose
ntensity (Fig. 1). A Cox regression model was used to model the
ime to the ﬁrst event with dose intensity and covariates from
he reduced multivariate model. Modeling was performed with all
ombinations of lags from 0 to 270 days and windows from 1 to
80 days. For each category or subcategory of event considered, a
eat map  of the percent change in relative risk (per 15-mg/d change
n average dose intensity) for all combinations of lag and window
ver this range was created. This heat map  was used to identify the
ag/window combinations most predictive of increased risk of the
vent with a 15-mg/d increase in dose intensity.
. Results
.1. PatientsAs of January 6, 2014, 683 patients across the phase 1, the phase
 PACE, and the phase 3 EPIC trials had received ponatinib. Median
uration of treatment was 7.4 months, with a median dose intensity
f 37.2 mg/d. The pooled analysis contained 671 ponatinib-treatedpatients, as 12 patients had 1 or more missing covariates and
were therefore excluded. Although most patients initially received
ponatinib 45 mg  once daily, individual dose intensities varied with
dose reductions and interruptions, and the median dose intensity
was higher in advanced-phase patients than in chronic-phase CML
patients. The duration of follow-up differed across the 3 studies and
was longer in the chronic-phase CML  patients. Primary results of
the phase 1 trial [12], the PACE trial [10], and the EPIC trial [13] have
been reported. In this pooled analysis, patients received 45 mg/d
on about half of all dosing days, and received lower doses or no
treatment (as part of a dose interruption) on the remaining days
(Table 1).
3.2. Distribution of covariates
Notable differences were observed in the distribution of covari-
ates for arterial occlusive events and venous thromboembolic
events by dose-intensity quartile, as summarized in Table 2. His-
tory of diabetes mellitus, history of ischemic disease, older age, and
longer time from diagnosis to ﬁrst dose were more frequent in the
lower 2 dose-intensity quartiles, while the lowest baseline platelet
and neutrophil counts were found in the highest dose-intensity
quartile. Thus, multivariate analyses were needed to remove the
inﬂuence of these factors on outcomes when evaluating the impact
of ponatinib dose intensity on adverse events.
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Table  3
Adverse events associated with ponatinib dose intensity: reduced multivariate logistic regression analyses (N = 671).
Event (number of patients with
event prior to last dose)
Odds ratio for 15-mg/d
increase in dose
intensity
P value Other signiﬁcant covariates
Pancreatitis (n = 45) 2.7 <0.001* History of diabetes
Rash (n = 266) 2.4 <0.001* Baseline platelet count Time from diagnosis to ﬁrst dose
Cardiac failure (n = 38) 2.3 0.001* History of ischemia Age at study entry Baseline neutrophil count
Cardiovascular event (n = 58) 2.0 <0.001* History of ischemia Age at study entry Time from diagnosis to ﬁrst dose
Thrombocytopenia (n = 237) 1.9 <0.001* Time from diagnosis to ﬁrst dose
Increased lipase (n = 142) 1.9 <0.001* Age at study entry Baseline neutrophil count Number of prior TKIs
Arterial occlusive event (n = 102) 1.7 <0.001* History of ischemia Age at study entry Time from diagnosis to ﬁrst dose
Arthralgia (n = 181) 1.6 <0.001* History of diabetes Baseline platelet count Number of prior TKIs
Increased AST (n = 88) 1.6 0.002* –
Increased ALT (n = 101) 1.6 0.002* –
Cerebrovascular event (n = 30) 1.4 0.13 Age at study entry Time from diagnosis to ﬁrst dose
Venous thromboembolic event (n = 20) 1.4 0.23 Baseline neutrophil count
Hypertriglyceridemia (n = 35) 1.4 0.16 –
Hypertension (n = 158) 1.3 0.02* Baseline platelet count
Peripheral vascular event (n = 35) 1.2 0.41 History of diabetes Age at study entry Baseline platelet count Number of prior TKIs
Neutropenia (n = 122) 1.2 0.21 Baseline neutrophil count Number of prior TKIs
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TKI, tyrosine kinase inhibitor.
* P < 0.05; indicates statistically signiﬁcant association with dose intensity.
Table 4
Prognostic factors for arterial occlusive events: univariate and multivariate logistic regression analyses (N = 671).
Covariate Univariate Multivariate (full) Multivariate (reduced)a
Odds ratio P value Odds ratio P value Odds ratio P value
Dose intensity 1.12 0.39 1.71 <0.001* 1.71 <0.001*
History of diabetes 2.06 0.006* 1.60 0.11 1.59 0.11
History of ischemic disease 3.33 <0.001* 2.64 <0.001* 2.65 <0.001*
Age at study entry 1.70 <0.001* 1.63 <0.001* 1.63 <0.001*
Log baseline platelet count 1.20 0.41 1.36 0.26 1.40 0.17
Log  baseline neutrophil count 1.06 0.67 1.04 0.83
Number of prior TKIs 1.37 <0.001* 1.20 0.10 1.20 0.10
Time  from diagnosis to ﬁrst dose 2.09 <0.001* 1.58 <0.05* 1.59 <0.05*
TKI, tyrosine kinase inhibitor.
Odds ratios are based on 15-mg/d increments for dose intensity, yes/no for history of diabetes and history of ischemic disease, 10-year increments for age at study entry and
time  from diagnosis to ﬁrst dose, 1-log increments for log baseline platelet count and log baseline neutrophil count (10-fold increments for baseline laboratory values), and
increments of 1 TKI for number of prior TKIs.
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* P < 0.05; indicates statistically signiﬁcant association. Time from diagnosis to 
reduced) models, respectively.
.3. Dose intensity and safety
After adjusting for covariates, we observed signiﬁcant associa-
ions between dose intensity and most adverse events by reduced
ultivariate logistic regression analysis, with the strongest associ-
tions (odds ratios >2) seen for pancreatitis, rash, and cardiac failure
Table 3). Other strong associations with dose intensity (odds ratios
1.5) were observed for cardiovascular events, thrombocytope-
ia, increased lipase, arterial occlusive events, arthralgia, increased
spartate aminotransferase, and increased alanine aminotrans-
erase; hypertension was also signiﬁcantly correlated with dose
ntensity, though more weakly (odds ratio = 1.3). The associations
etween dose intensity and cerebrovascular events, venous throm-
oembolic events, hypertriglyceridemia, and peripheral vascular
vents were not signiﬁcant; however, these events were relatively
nfrequent, thus reducing the power to detect an association. Neu-
ropenia was the only event that occurred in more than 10% of
atients and did not have a statistically signiﬁcant association with
ose intensity. Lack of an association with dose intensity may  be
ttributed to these events occurring early, generally, and often dur-
ng a dose reduction following thrombocytopenia.Dose intensity, history of ischemic disease, and age were the
trongest independent predictors of increased risk of an arterial
cclusive event (Table 4). The odds ratio for dose intensity in this
odel was 1.71, which results in a prediction of an approximatelyose had P values of 0.0478 and 0.0463 in the multivariate (full) and multivariate
33% reduction in the risk of an arterial occlusive event for each
15-mg/d decrease in average ponatinib dose intensity (Fig. 2).Fig. 2. Ponatinib dose intensity and risk of arterial occlusive events. The estimated
rate of arterial occlusive events based on dose intensity is shown for patients with
the mean covariate levels in the reduced multivariate model. The curves would shift
up or down depending on the level of covariates used in the model. Orange lines
represent 95% conﬁdence intervals.
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Fig. 3. Time to ﬁrst arterial occlusive event (any arterial occlusive event [A] or a cardiovascular [C], cerebrovascular [E], or peripheral vascular [G] event) and relation of
events to ponatinib dose lag and window. Orange lines in time-to-event plots (A, C, E, and G) represent 95% conﬁdence intervals. Heat maps (B, D, F, and H) show percent
change in relative risk per 15-mg/d change in average ponatinib dose intensity according to different combinations of ponatinib dose lag and window.
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Fig. 4. Time to ﬁrst venous thromboembolic event and relation of event to ponatinib dos
intervals. Heat map  (B) shows percent change in relative risk per 15-mg/d change in aver
lag  and window.
Table 5
Ponatinib dose lag and risk of arterial occlusive and venous thromboembolic events.
Event Model with greatest estimated risk increase
Lag (days) % risk increase
per 15 mg/d
P value
Arterial occlusive 198 87.9 <0.001*
Cardiovascular 132 66.6 0.006*
Cerebrovascular 34 89.2 0.002*
Peripheral vascular 142 66.5 0.02*
Venous thromboembolic 20 24.1 0.37
* P < 0.05; indicates statistically signiﬁcant association.
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dose-related adverse events might possibly be best managed with
dose reduction. However, time-to-event modeling indicated that
the lag between reductions in dose and the maximum model-.4. Time-to-event modeling
To address limitations, additional analyses were conducted that
urther incorporated the timing of the event, the timing of dos-
ng, and the same covariates used in the logistic regression models.
enerally, the rates of arterial occlusive events and venous throm-
oembolic events appeared to be relatively constant over time
Figs. 3 A, C, E, G, and 4 A), with some suggestion that cardiovas-
ular events occurred earlier in the studies and peripheral vascular
nd cerebrovascular events tended to occur later. The relationships
etween ponatinib dose lag/window and the development of arte-
ial occlusive events and venous thromboembolic events for all
odels are shown in Figs. 3 B, D, F, H, and 4 B; Table 5 summarizes
he models with the highest magnitude of association with dose
or each event type. Statistically signiﬁcant associations between
ose intensity and event risk were revealed for arterial occlusive
vents, including cardiovascular events, cerebrovascular events,
nd peripheral vascular events. Venous thromboembolic events
ere not statistically signiﬁcantly associated with dose intensity
n any of the ﬁtted models. Overall, the model-predicted percent
hange in relative risk (per 15-mg/d change in average dose inten-
ity) was inﬂuenced more by lag than by window. Both the lag and
he maximum model-predicted change in relative risk varied by
vent type; the lag was about 6 months (198 days) for arterial occlu-
ive events, and the change in relative risk ranged from 67% to 89%
er 15-mg/d dose increase (Table 5).
These more powerful time-to-event models were generally
onsistent with the logistic models, although the models for the
henomena occurring later, such as cerebrovascular and periph-
ral vascular events, showed a stronger association and a greater
agnitude of risk based on dose intensity when compared with theogistic models.e lag and window. Orange lines in time-to-event plot (A) represent 95% conﬁdence
age ponatinib dose intensity according to different combinations of ponatinib dose
4. Discussion
In this exploratory post hoc analysis, we pooled data from the
phase 1 dose-ﬁnding trial, the phase 2 PACE trial, and the phase
3 EPIC trial of ponatinib in patients with CML, Ph+ ALL, or other
hematologic malignancies to determine the impact of dose inten-
sity on select adverse events. Dose modiﬁcations leading to lower
dose intensity were more common in older patients and in patients
with medical histories of diabetes and ischemic disease. Patients
with lower baseline platelet and neutrophil counts were generally
able to tolerate a higher dose of ponatinib. After adjusting for these
factors, analyses demonstrated that higher ponatinib doses were
associated with higher rates of most adverse events. The greatest
magnitude of association with ponatinib dose was observed with
pancreatitis, rash, and cardiac failure (not venous thromboembolic
events). Notably, ponatinib dose was also highly signiﬁcantly asso-
ciated with the occurrence of arterial occlusive events as well as
the cardiovascular subset. In addition to dose, older age and prior
history of ischemic disease were independent factors strongly asso-
ciated with the development of arterial occlusive events, suggesting
that careful attention to dose is warranted in patients with these
risk factors.
These ﬁndings support a potential causal relationship between
ponatinib dose intensity and the identiﬁed dose-related adverse
events, and expand on the ﬁndings of prior phase 2 PACE ret-
rospective analyses suggesting a causal relationship [11]. Other
prior analyses of PACE data have shown that efﬁcacy was retained
at lower doses [14]. Therefore, effective management of patients
receiving ponatinib might possibly be achieved with dose mod-
iﬁcation, such that efﬁcacy and safety are balanced. While it is
possible that dose reduction alone might not completely prevent
dose-related adverse events, the extent to which lower doses miti-
gate these events can be investigated prospectively. Randomized
clinical trials examining approaches to achieve a lower average
dose intensity of ponatinib in patients with CML  or Ph+ ALL are
needed to conﬁrm the observations in the current analysis. Where
feasible, a more detailed investigation of cardiovascular risk factors
and all key cardiovascular and metabolic parameters (including
general vascular health as determined by ultrasound; the ankle-
brachial index; and cholesterol, glucose, and hemoglobin A1c levels)
should be performed before and during therapy, regardless of dose.
This analysis informs the usual approach to dose reduction as
a method for adverse event management. The data suggest thatpredicted percent change in relative risk (per 15-mg/d change in
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verage dose intensity) varied by event type. In general, measures
hat lower dose intensity (starting treatment at doses <45 mg/d
nd/or reducing dose after response) are predicted to lower event
ates. However, the results of the time-to-event analyses suggest
hat there may  be up to a 6-month delay following dose alteration
efore a change in risk manifests for some arterial occlusive events.
or patients in whom reduced doses of ponatinib may  not be desir-
ble (such as those with advanced disease), alternate strategies,
ncluding combination therapy [15], may  be required.
These analyses included as many patients as possible from the
ooled study population to enable a robust assessment of the rela-
ionship of dose intensity and other covariates to the selected
dverse events. However, the study is not without limitation. The
ncluded phase 3 trial was conducted in previously untreated
atients, in contrast to the heavily pretreated populations of the
hase 1 and 2 trials, and had a shorter follow-up period. Further,
atients who had dose adjustments tended to have other adverse
linical characteristics. We  attempted to account for these covari-
tes; nevertheless, additional salient clinical factors may  have gone
nmeasured. For example, none of the 3 studies included in the
ooled analysis involved comprehensive vascular pre-screening
ssessments; therefore, patient-speciﬁc risk factors may  have con-
ributed to the occurrence of arterial occlusive events. Previous
ork has suggested that currently prescribed BCR-ABL1 TKIs,
ncluding dasatinib, nilotinib, and ponatinib, are associated with
ardiovascular adverse events [16–22]. Relevant clinical factors,
uch as the presence of atherosclerosis, should thus be assessed in
ny patient treated with BCR-ABL1 TKIs, including ponatinib, before
nd during treatment.
Other potential limitations include aspects of the logistic regres-
ion analysis. Speciﬁcally, the logistic regression analysis did not
ccount for time on study, which varied among the trials. Because
ose usually decreases over time, this can create a bias in which
he dose intensity approximation could overestimate the true dose
ntensity for events that happen early and may  underestimate the
rue effect in events that occur later. Moreover, the logistic model
mployed in these analyses treats the dose intensity in a patient
ho drops out early the same as that in a patient who  has a much
onger exposure without an event. It should also be noted that the
ailure to identify a signiﬁcant association in this analysis may  be
ue to insufﬁcient statistical power to detect such a relationship
etween dose intensity and certain rare events.
As previously noted, cardiovascular, cerebrovascular, and
eripheral vascular events have been reported in patients treated
ith other BCR-ABL1 TKIs. In a trial of nilotinib in newly diagnosed
ML  patients, the cardiovascular event rate, including arterial vas-
ular occlusive events, was 9.3% and 15.2% with nilotinib 300 mg
wice daily and 400 mg  twice daily, respectively, after a median of 5
ears on therapy [23]. In a trial of dasatinib in newly diagnosed CML
atients, cardiovascular adverse events included cardiac ischemic
vents (3.9%), cardiac-related ﬂuid retention (8.5%), conduction
ystem abnormalities (7.0%), and transient ischemic attacks (0.8%),
ith 5 years of follow-up [24]. Dasatinib is also associated with
ulmonary hypertension and may  increase risk of pulmonary arte-
ial hypertension [24,25]. It is noteworthy that the most potent
CR-ABL1 TKIs have similar vascular adverse event proﬁles. The
esults presented here suggest that this association is a dose-related
henomenon, and prospective, randomized data for nilotinib at
00 mg  and 400 mg  twice daily corroborate this ﬁnding [23]. Pona-
inib is currently the only BCR-ABL1 TKI that is active against
he T315I mutant and approved for refractory CML and Ph+ ALL
7–9,23,24,26–29]. Given that the T315I mutation is associated
ith disease progression and compromised survival [3,30–33], the
ppropriate use of ponatinib is critical to the achievement of posi-
ive long-term outcomes in these patients. Among patients without
he T315I mutation, daily dose could also likely be optimized toearch 48 (2016) 84–91
achieve and maintain efﬁcacy, as previously reported [10,12], while
minimizing serious adverse events.
5. Conclusion
The results of these exploratory analyses support the prospec-
tive investigation of approaches to lowering the average dose
intensity of ponatinib, such as starting at lower doses and/or reduc-
ing dose after response, to optimize patient outcomes. Two such
studies, both randomized clinical trials, are currently enrolling
patients: OPTIC, a phase 2 dose-ranging trial (NCT02467270) in
patients with refractory CML  to prospectively evaluate the efﬁ-
cacy and safety of 3 starting doses (15 mg/d, 30 mg/d, and 45 mg/d,
with reductions to 15 mg/d upon achievement of major cyto-
genetic response), and OPTIC-2L, a phase 3 comparative trial
(NCT02627677) of the efﬁcacy and safety of 2 starting doses of
ponatinib (30 mg/d and 15 mg/d) vs. nilotinib (400 mg  twice daily)
in patients with imatinib-resistant CP-CML.
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